^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
Excerpt:
Eight of nine of patients with objective responses who were assessable by fluorescence in-situ hybridisation (FISH) had an increased EGFR copy number. By contrast, one of 21 non-responders assessable by FISH had an increased EGFR copy number (p<0.0001 for responders vs non-responders, Fisher's exact test).
DOI:
10.1016/S1470-2045(05)70102-9
Source:
Title:
EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis
Excerpt:
It shows high EFGR GCN had benefit effect on OS when treated with cetuximab or panitumumab in mCRC patients...In MoAbs subgroup, increased EGFR GCN was statistically significantly associated with increased ORR in studies of cetuximab treated patients (HR=6.296; 95% CI: 3.990-9.935) and panitumumab treated patients (HR=34.517; 95% CI: 1.826-652.370).
DOI:
10.3978/j.issn.1000-9604.2014.01.10
